Navigation Links
Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
Date:9/14/2010

g, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). Optimer has completed two Phase 3 trials of fidaxomicin for the treatment of CDI demonstrating that fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurrence within four weeks of completing therapy) as well as statistically superior in reducing recurrences of CDI by up to 50% when compared with vancomycin, the only FDA approved product for CDI. Optimer has also successfully completed two Phase 3 trials of Pruvel™ a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-looking Statements Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the ability of fidaxomicin to treat CDI and address current treatment limitations, expectations regarding regulatory filings and the potential to bring fidaxomicin to the market. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research a
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
2. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
4. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
6. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
7. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
8. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
9. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
10. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
11. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery company, ... Memorandum of Understanding with the Feinstein Institute for ... York to collaborate with the objective ... The collaboration brings together the drug discovery ... expertise of the Feinstein Institute in neurosciences and ...
(Date:4/16/2015)... OSAKA, Japan , April 16, 2015 ... of Kyoto University and Takeda Pharmaceutical Company Limited ... to develop clinical applications of induced pluripotent stem ... mellitus, neurological disorders and cancer immunotherapy. The "Takeda-CiRA ... designed to expedite multiple research projects for drug ...
(Date:4/16/2015)... 16, 2015  Schulman Associates IRB, Inc., the industry-leading ... a long-term lease on Laboratory Drive in the heart ... . The location will house review board and service ... quality reviews and customer service to clients. ... Schulman in the deal, while Capital Associates Management, LLC ...
(Date:4/16/2015)... WESTON, Mass. , April 16, 2015  In recognition ... has collaborated with hemophilia advocacy groups to illuminate more than ... , including Boston,s Zakim Bridge ... New Orleans, Mercedes-Benz Superdome and ... will occur during the evening of April 17, and coincide ...
Breaking Biology Technology:Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4
... MichBio, the association for,Michigan,s life sciences ... Directory and Resources Guide, a complete listing ... includes editorial pages with articles,on Michigan,s SmartZones, ... Michigan Universities Commercialization Initiative,and Core Technology Alliance, ...
... ,Exelixis, Inc. (Nasdaq: EXEL ) today announced the ... stock. The net proceeds of the,offering are approximately $71.8 ... in the offering are being sold by,Exelixis. Exelixis has ... to an additional 1,050,000 shares of common stock. Goldman,Sachs ...
... Fla., Sept. 13 An affiliate of,Phlo ... that the,distribution of its performance/vitality product, AQUISS(TM), ... the Oakland region, an expansive and,diverse territory, ... Company,believes that the expansion into additional distribution ...
Cached Biology Technology:AQUISS Expands Into Significant New Territory 2
(Date:3/23/2015)... SoundView Technology Group issues a new research update ... Wocket smart wallet. SoundView was one of the selected user groups ... the Wocket in multiple scenarios and outlets. ... retailers, making both debit and credit card payments.  ... the company meets their plans in 2015, it would push ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/17/2015)... March 17, 2015 MedNet Solutions ... in clinical study management systems, is pleased to ... at ARENA,s Outsourcing in Clinical Trials Southeast conference ... provides an excellent forum for MedNet to showcase ... affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... Molecular Biology Organization (EMBO) announced today the selection of ... 2007 beneficiaries of its prestigious Young Investigator Programme. ... outstanding young life scientists in Europe. Recipients receive academic, ... years of their independent careers. Selected by ...
... greenhouse gas emissions in the Great Lakes region ... and a serious look at sustainabilityways of protecting ... team of professors at Rochester Institute of Technology ... Lakes Maritime Research Institute to determine whether marine ...
... three months of daily, vigorous physical activity in overweight ... researchers say. Studies of about 200 overweight, inactive ... program reduces body fat and improves bone density. ... into lean, healthy kids? No. They are still overweight ...
Cached Biology News:18 young scientists join EMBO Young Investigator network 2RIT to study air pollution and greenhouse gas emissions in the Great Lakes region 2Exercise improves thinking, reduces diabetes risk in overweight children 2Exercise improves thinking, reduces diabetes risk in overweight children 3